- EU approved AstraZeneca’s Etcamah with CDK4/6 inhibitor as first‑line treatment for advanced ER+ breast cancer — regulatory OK for this indication and combination.
- AstraZeneca’s cliramitug, a Phase 3 TTR‑fibril‑depleting antibody for ATTR‑CM, moved royalty rights to Royalty Pharma; Phase 3 DepleTTR‑CM readout expected in 2028 — key milestone for AZN traders
TradingView
Key facts: Etcamah+CDK4/6 Approved; Cliramitug Rights to Royalty Pharma
- Sources
- TradingView
- Active symbols
- LSE:AZN
- Language
- English (India)
EU approved AstraZeneca’s Etcamah with CDK4/6 inhibitor as first‑line treatment for advanced ER+ breast cancer — regulatory OK for this indication and combination.AstraZeneca’s cli